Skip to main content

Advertisement

SpringerLink
Log in

New Adjuvant Trial Designs in Colon Cancer

  • Adjuvant Therapy for Colon Cancers (AB Benson III and A de Gramont, Section Editors)
  • Published:
Current Colorectal Cancer Reports

Abstract

The treatment of colon cancer has evolved significantly since the discovery of 5-fluorouracil, and with continued innovation, it will continue to advance for the foreseeable future. In this review, we identify and discuss novel adjuvant trial designs which are currently being employed and that are forthcoming in the treatment of colon cancer. Novel approaches include investigation into whether a shorter duration of adjuvant therapy is as effective as the current standard, whether there is benefit of neoadjuvant chemotherapy in the treatment of nonmetastatic colon cancer, the role of circulating tumor cells and cell-free DNA on clinical decision making and their impact on long-term outcomes, identification, and individualized treatment of molecular subgroups of colon cancer (i.e., HER2 amplified, microsatellite instable, BRAF V600E mutated, etc.) and the efficacy of targeting cancer stem cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Moertel CG et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322(6):352–8.

    Article  CAS  PubMed  Google Scholar 

  2. O'Connell MJ et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998;16(1):295–300.

    PubMed  Google Scholar 

  3. O'Connell MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997;15(1):246–50.

    PubMed  Google Scholar 

  4. Wolmark N et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993;11(10):1879–87.

    CAS  PubMed  Google Scholar 

  5. Wolmark N et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999;17(11):3553–9.

    CAS  PubMed  Google Scholar 

  6. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet, 1995. 345(8955): p. 939-44.

  7. Andre T et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol. 2003;21(15):2896–903.

    Article  CAS  PubMed  Google Scholar 

  8. Haller DG et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005;23(34):8671–8.

    Article  PubMed  Google Scholar 

  9. Andre T et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.

    Article  CAS  PubMed  Google Scholar 

  10. Andre T et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16.

    Article  CAS  PubMed  Google Scholar 

  11. Haller DG et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11):1465–71.

    Article  CAS  PubMed  Google Scholar 

  12. Kuebler JP et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198–204.

    Article  CAS  PubMed  Google Scholar 

  13. Gray R et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–9.

    Article  PubMed  Google Scholar 

  14. Tournigand C et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol. 2012;30(27):3353–60.

    Article  CAS  PubMed  Google Scholar 

  15. Sargent DJ et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345(15):1091–7.

    Article  CAS  PubMed  Google Scholar 

  16. McCleary NJ et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol. 2013;31(20):2600–6. Analysis from seven adjuvant trials which showed that there was reduced benefit in the addition of oxaliplatin to fluoropyrimidine therapy in the adjuvant setting for patients aged 70 or older.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Papadimitriou CA et al. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study. BMC Med. 2011;9:10.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Saltz LB et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25(23):3456–61.

    Article  CAS  PubMed  Google Scholar 

  19. Van Cutsem E et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27(19):3117–25.

    Article  PubMed  Google Scholar 

  20. Ychou M et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol. 2009;20(4):674–80.

    Article  CAS  PubMed  Google Scholar 

  21. de Gramont A et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13(12):1225–33.

    Article  PubMed  Google Scholar 

  22. Allegra CJ et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29(1):11–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Allegra CJ et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol. 2013;31(3):359–64. Analysis of 2,673 patients which showed that 12 months of bevacizumab in addition to mFOLFOX6 did not significantly lengthen DFS or OS in patients with stage II or III colon cancer.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Taieb J et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(8):862–73. Phase III study which showed that the addition of cetuximab to FOLFOX4 did not significantly lengthen DFS in patients with stage III, KRAS exon 2 wild-type, colon cancer.

    Article  CAS  PubMed  Google Scholar 

  25. Alberts SR et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307(13):1383–93.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Andre T et al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Curr Colorectal Cancer Rep. 2013;9:261–9. Details the design and rationale for an ongoing international collaboration to determine if three months of oxaliplatin-based adjuvant therapy is non-inferior to the standard six months in patients with stage III colon cancer.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Zeghari-Squalli N et al. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res. 1999;5(5):1189–96.

    CAS  PubMed  Google Scholar 

  28. Raymond E et al. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther. 2002;1(3):227–35.

    CAS  PubMed  Google Scholar 

  29. Falcone A et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol. 2002;20(19):4006–14.

    Article  CAS  PubMed  Google Scholar 

  30. Masi G et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol. 2004;15(12):1766–72.

    Article  CAS  PubMed  Google Scholar 

  31. Masi G et al. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol. 2006;13(1):58–65.

    Article  PubMed  Google Scholar 

  32. Falcone A et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–6.

    Article  CAS  PubMed  Google Scholar 

  33. Van Cutsem E et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(19):3117–25.

    Article  Google Scholar 

  34. Goldberg RM et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23–30.

    Article  CAS  PubMed  Google Scholar 

  35. Groot Koerkamp B et al. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol. 2013;20(7):2156–65. Meta-analysis which showed that among colon cancer patients, either with resectable liver metastases or widespread metastatic disease, those with detectable circulating tumor cells in peripheral blood had worse PFS and OS.

    Article  PubMed  Google Scholar 

  36. Rahbari NN et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 2010;138(5):1714–26.

    Article  PubMed  Google Scholar 

  37. Stoecklein NH, Klein CA. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer. 2010;126(3):589–98.

    Article  CAS  PubMed  Google Scholar 

  38. Park CH, Bergsagel DE, McCulloch EA. Mouse myeloma tumor stem cells: a primary cell culture assay. J Natl Cancer Inst. 1971;46(2):411–22.

    CAS  PubMed  Google Scholar 

  39. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730–7.

    Article  CAS  PubMed  Google Scholar 

  40. O'Brien CA et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445(7123):106–10.

    Article  PubMed  Google Scholar 

  41. Ricci-Vitiani L et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111–5.

    Article  CAS  PubMed  Google Scholar 

  42. Wulf GG et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood. 2001;98(4):1166–73.

    Article  CAS  PubMed  Google Scholar 

  43. Pearce DJ et al. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells. 2005;23(6):752–60.

    Article  CAS  PubMed  Google Scholar 

  44. Todaro M et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2007;1(4):389–402.

    Article  CAS  PubMed  Google Scholar 

  45. Weisenberger DJ et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38(7):787–93.

    Article  CAS  PubMed  Google Scholar 

  46. Goel A et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 2007;132(1):127–38.

    Article  CAS  PubMed  Google Scholar 

  47. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609–18.

    Article  CAS  PubMed  Google Scholar 

  48. Ribic CM et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247–57.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Sargent DJ et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Llosa NJ et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43–51. First demonstrated link between microsatellite instable colon cancers and the upregulated expression of immune check-points in the tumor microenvironment.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. Dolcetti R et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol. 1999;154(6):1805–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Alexander J et al. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001;158(2):527–35.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. Timmermann B et al. Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One. 2010;5(12):e15661.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  54. Eshleman JR et al. Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer. Oncogene. 1995;10(1):33–7.

    CAS  PubMed  Google Scholar 

  55. Le DT et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509–20. Phase II study which showed benefit of pembrolizumab in the treatment of mismatch repair deficient colon cancers. Mismatch repair status predicted clinical benefit with PD-1 blockade, with no benefit noted in those with mismatch repair proficient tumors.

    Article  CAS  PubMed  Google Scholar 

  56. Blok EJ et al. Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer. Clin Med Insights Oncol. 2013;7:41–51.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  57. Missiaglia E et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25(10):1995–2001. Analysis of clinicopathologic data from patients enrolled in the PETACC-3 trial which showed that key differences exist in the molecular features of colon cancer depending on tumor location.

    Article  CAS  PubMed  Google Scholar 

  58. Bertotti A et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1(6):508–23.

    Article  CAS  PubMed  Google Scholar 

  59. Ramanathan RK et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest. 2004;22(6):858–65.

    Article  CAS  PubMed  Google Scholar 

  60. Clark J, Niedzwiecki D, Hollis D, Mayer R. Phase II trial of 5-fluorouracil (5-FU), leucovorin (LV), oxaliplatin (Ox), and trastuzumab (T) for patients with metastatic colorectal cancer (CRC) refractory to initial therapy (abstract 3584). Proceedings of ASCO, 2003(22): p. 891.

  61. Foxtrot Collaborative G. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012;13(11):1152–60.

    Article  Google Scholar 

  62. Huh JW et al. Prognostic value of preoperative radiological staging assessed by computed tomography in patients with nonmetastatic colon cancer. Ann Oncol. 2012;23(5):1198–206.

    Article  CAS  PubMed  Google Scholar 

  63. Arredondo J et al. Tumor response assessment in locally advanced colon cancer after neoadjuvant chemotherapy. J Gastrointest Oncol. 2014;5(2):104–11. Retrospective analysis of 44 patients with localized early stage colon cancer, treated with neoadjuvant oxaliplatin/fluoropyrimidine therapy, which showed significant tumor shrinkage following neoadjuvant chemotherapy and reasonable accuracy of CT-based staging.

    PubMed Central  PubMed  Google Scholar 

  64. Balthazar EJ et al. Carcinoma of the colon: detection and preoperative staging by CT. AJR Am J Roentgenol. 1988;150(2):301–6.

    Article  CAS  PubMed  Google Scholar 

  65. Freeny PC et al. Colorectal carcinoma evaluation with CT: preoperative staging and detection of postoperative recurrence. Radiology. 1986;158(2):347–53.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Alexis D. Leal declares that she has no conflict of interest.

Joleen Hubbard has received research funding through grants to Mayo Clinic from Boston Biomedical, Inc., and Senhwa Biosciences, Inc., and has received compensation from Bayer for service as a consultant.

Daniel Sargent has received compensation from Roche for service as a consultant.

Axel Grothey has received research funding through grants to Mayo Clinic from Genentech, Eisai, Sanofi, Eli Lilly, and Boston Biomedical, Inc.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA

    Alexis D. Leal, Joleen Hubbard & Axel Grothey

  2. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA

    Daniel Sargent

Authors
  1. Alexis D. Leal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joleen Hubbard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Sargent
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Axel Grothey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Axel Grothey.

Additional information

This article is part of the Topical Collection on Adjuvant Therapy for Colon Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leal, A.D., Hubbard, J., Sargent, D. et al. New Adjuvant Trial Designs in Colon Cancer. Curr Colorectal Cancer Rep 11, 326–334 (2015). https://doi.org/10.1007/s11888-015-0297-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-015-0297-y

Keywords

Search

Navigation